Business Wire

CA-ARMIS

12.12.2023 14:01:40 CET | Business Wire | Press release

Share
Armis Named Leader in Three Q4 2023 Quadrant SPARK Matrix™ Reports

Armis, the asset intelligence cybersecurity company, today announced that it has been named a leader by analyst group Quadrant Knowledge Solutions in three 2023 SPARK Matrix™ reports for Q4 2023. The reports: SPARK Matrix™: Vulnerability Management, Q4 2023, SPARK Matrix™: Operational Technology (OT) Security, Q4 2023, and SPARK Matrix™: Connected Medical Device Security Solutions, Q4 2023, place three Armis Centrix™ solutions as a Technology Leader with significant customer impact in the areas of Vulnerability Management, Operational Technology Security and Connected Medical Device Security.

“Our Leader position in these three reports is a testament to our commitment to innovation and customer success, and helping organizations see, protect and manage their entire attack surface in real-time,” said Dana Gilboa, Chief Product Officer of Armis. “We are extremely proud that Armis is positioned as a Leader on both the Technology Leader axis and the Customer Impact axis for all three reports. We also want to extend a sincere thank you to the Armis customers who took the time to provide feedback on Armis to Quadrant Knowledge Solutions.”

The SPARK Matrix™ reports analyzed three of Armis’ four core solutions: Vulnerability Management, OT/IoT Security, and Medical Device Security, which are all built on Armis Centrix™, the Armis cyber exposure management platform. Powered by the Armis AI-driven Asset Intelligence Engine, Armis Centrix™ is a seamless, frictionless, cloud-based platform that proactively identifies all cyber asset risks, remediates vulnerabilities, blocks threats and protects the entire attack surface.

SPARK Matrix™ reports analyze the vendor landscape of a technology category and vendor product capabilities. Vendors are evaluated according to their product offerings, market share and customer satisfaction to help CIOs and CISOs make informed technology decisions.

When evaluating why Armis is a technology leader in each of these three core areas, Quadrant Knowledge Solutions shared in its reports:

  • Vulnerability Management - “Armis Centrix™ for Vulnerability Prioritization and Remediation bridges critical coverage gaps unattended by Vulnerability assessment tools with aggregation of details such as ownership and location to create full visibility of the attack surface. Armis Centrix™ for Vulnerability Prioritization and Remediation provides holistic visibility into the user’s overall risk and attack surface. The platform also provides the business context of business-critical assets based on their roles. Armis Centrix™ Asset Vulnerability Prioritization and Remediation helps the organization reduce its attack surface by analyzing attributes of devices and overlaying threat intel as a part of the analysis.”
  • Operational Technology Security - “Armis Centrix™ for OT/IoT security enables organizations to see and secure OT/IOT networks and physical assets, ensure uptime, and build an effective & comprehensive security strategy. It is powered by Armis’ AI-driven Asset Intelligence Engine and oversees, secures, protects, and manages a wide range of assets in real-time. The cloud-based platform proactively mitigates all cyber asset risks, remediates vulnerabilities, blocks threats, and protects the entire attack surface. Armis for OT/IoT security provides deep visibility to all OT assets as well as to the OT/ICS networks and environment. It allows companies to manage the OT/IT convergence, bridge the IT / OT gap and protect OT networks, monitor connectivity, and track behavior.”
  • Connected Medical Device Security - “Armis Centrix™ for Medical Device Security offers features like real-time complete visibility into medical device inventory, information regarding device usage for increasing utilization efficiency, medical device risk assessment based on vulnerabilities, identifying Protected Health Information (PHI) breaches, identifying and remediating threats, and automating security of medical devices. The product is also equipped with an Asset Intelligence Engine with over 20 million device profiles, and the AI-powered Armis Standard Query.”

Learn more about each of these Quadrant Knowledge Solutions reports at the below links:

To read our blog, please visit: https://www.armis.com/blog/armis-is-named-a-leader-in-three-2023-quadrant-spark-matrix-reports/

For additional analyst reports sharing insights about Armis Centrix™, go here: https://www.armis.com/resources/?type=analyst-reports

About Armis

Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231212672034/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye